Vitality Watch

Dossier pubmed other 19-sep-2026
Doesn't fit the ladder

Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment.

Briefing card

Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment.
Stage: other · pubmed · 19-sep-2026

A comment addresses oral semaglutide versus DPP-4 inhibitors for reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s11739-026-04533-5

build build 880 · 2bcef25 · 2026-11-18